Search research articles
Contact Us
Filters
Showing results (31-40 of 144) with videos related to
Page
of 15
Sort By:
Investigational New Drugs
|
August 25, 2000
Phase II trial of pyrazoloacridine as second-line therapy for patients with unresectable or metastatic transitional cell carcinoma
P M Dodd, J A McCaffrey, M Mazumdar, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
November 26, 1999
Transgenic tobacco plants with reduced capability to detoxify reactive oxygen intermediates are hyperresponsive to pathogen infection
R Mittler, E H Herr, B L Orvar, et al.
The Journal of Urology
|
August 1, 1989
Mortality in pediatric paratesticular rhabdomyosarcoma: a multivariate analysis
M P LaQuaglia, F Ghavimi, G Heller, et al.
International Journal of Oncology
|
May 17, 2011
P53 nuclear overexpression and disease progression in ta-bladder carcinoma
A Sarkis, Z Zhang, C Cordoncardo, et al.
American Journal of Clinical Oncology
|
August 1, 1984
VP-16-213 and cisplatin in the treatment of patients with refractory germ cell tumors
G J Bosl, A Yagoda, W F Whitmore, et al.
Progress in Clinical and Biological Research
|
January 1, 1986
Clinical follow-up
O Yoshida, A Bono, J Braeckman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 1, 1985
VAB-6 as initial treatment of patients with advanced seminoma
G F Stanton, G J Bosl, W F Whitmore, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 1, 1995
Etoposide and cisplatin adjuvant therapy for patients with pathologic stage II germ cell tumors
R J Motzer, J Sheinfeld, M Mazumdar, et al.
The New England Journal of Medicine
|
May 20, 1971
Influence of aortocoronary bypass surgery on left ventricular performance
G Rees, J D Bristow, E L Kremkau, et al.
Cancer
|
March 26, 1999
Phase II trial of intermediate dose methotrexate in combination with vinblastine, doxorubicin, and cisplatin in patients with unresectable or metastatic transitional cell carcinoma
P M Dodd, J A McCaffrey, M Mazumdar, et al.
Page
of 15
Search research articles
Search
Showing results (31-40 of 144) with videos related to
Sort By:
Page
of 15
Investigational New Drugs
|
August 25, 2000
Phase II trial of pyrazoloacridine as second-line therapy for patients with unresectable or metastatic transitional cell carcinoma
P M Dodd, J A McCaffrey, M Mazumdar, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
November 26, 1999
Transgenic tobacco plants with reduced capability to detoxify reactive oxygen intermediates are hyperresponsive to pathogen infection
R Mittler, E H Herr, B L Orvar, et al.
The Journal of Urology
|
August 1, 1989
Mortality in pediatric paratesticular rhabdomyosarcoma: a multivariate analysis
M P LaQuaglia, F Ghavimi, G Heller, et al.
International Journal of Oncology
|
May 17, 2011
P53 nuclear overexpression and disease progression in ta-bladder carcinoma
A Sarkis, Z Zhang, C Cordoncardo, et al.
American Journal of Clinical Oncology
|
August 1, 1984
VP-16-213 and cisplatin in the treatment of patients with refractory germ cell tumors
G J Bosl, A Yagoda, W F Whitmore, et al.
Progress in Clinical and Biological Research
|
January 1, 1986
Clinical follow-up
O Yoshida, A Bono, J Braeckman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 1, 1985
VAB-6 as initial treatment of patients with advanced seminoma
G F Stanton, G J Bosl, W F Whitmore, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 1, 1995
Etoposide and cisplatin adjuvant therapy for patients with pathologic stage II germ cell tumors
R J Motzer, J Sheinfeld, M Mazumdar, et al.
The New England Journal of Medicine
|
May 20, 1971
Influence of aortocoronary bypass surgery on left ventricular performance
G Rees, J D Bristow, E L Kremkau, et al.
Cancer
|
March 26, 1999
Phase II trial of intermediate dose methotrexate in combination with vinblastine, doxorubicin, and cisplatin in patients with unresectable or metastatic transitional cell carcinoma
P M Dodd, J A McCaffrey, M Mazumdar, et al.
Page
of 15